Cost-Effectiveness Models in Age-Related Macular Degeneration: Issues and Challenges

Schmier, Jordana; Hulme-Lowe, Carolyn; Schmier, Jordana K; Hulme-Lowe, Carolyn K
March 2016
PharmacoEconomics;Mar2016, Vol. 34 Issue 3, p259
Academic Journal
journal article
Age-related macular degeneration (AMD) is a common ophthalmic condition that can have few symptoms in its early stage but can progress to major visual impairment. While there are no treatments for early-stage AMD, there are multiple modalities of treatment for advanced disease. Given the increasing prevalence of the disease, there are dozens of analyses of cost effectiveness of AMD treatments, but methods and approaches vary broadly. The goal of this review was to identify, characterize, and critique published models in AMD and provide guidance for their interpretation. After a literature review was performed to identify studies, and exclusion criteria applied to limit the review to studies comparing treatments for AMD, we compared methods across the 36 studies meeting the review criteria. To some extent, variation was related to targeting different audiences or acknowledging the most appropriate population for a given treatment. However, the review identified potential areas of uncertainty and difficulty in interpretation, particularly regarding duration of observation periods and the importance of visual acuity as an endpoint or a proxy for patient-reported utilities. We urge thoughtful consideration of these study characteristics when comparing results.


Related Articles

  • Anti-VEGF injections may not be preferred for AMD patients with poor baseline visual acuity. Pagnani, Michelle // Ocular Surgery News;3/25/2012, Vol. 30 Issue 6, p10 

    The article reports on a study which found that for those with age-related macular degeneration and poor baseline acuity, consideration of an alternative to anti-vascular epithelial growth factor (VEGF) therapy may be warranted.

  • Comparison studies of anti-VEGF agents a 'global effort'. Boyle, Erin L.; Harcharek, Alexandra; Hasson, Matt; Hsvidas, Cara; Nale, Patricia; Master, Joseph; Pagnani, Michelle; Preston, Courtney // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p25 

    The article reports on the presentation by doctor Daniel F. Martin on the comparison studies and international effort to understand the differences between the two anti-vascular endothelial growth factor (VEGF) agents, ranibizumab and bevacizumab.

  • Combining anti-PDGF with anti-VEGF may improve visual acuity, reduce AMD treatment burden.  // Ocular Surgery News;7/25/2012, Vol. 30 Issue 14, Special section p1 

    The article states that the complex disease process 'Advanced age-related macular degeneration be treated by modulating two factors 'VEGF' and 'PDGF'.When anti VEGF therapy is combined with anti platelet derived growth factor aptamer it leads to a better visual outcome.The limitation of anti...

  • Ranibizumab: points to consider when using it to treat neovascular age-related macular degeneration according to EU labelling. Lyseng-Williamson, Katherine; Frampton, James // Drugs & Therapy Perspectives;Sep2013, Vol. 29 Issue 9, p268 

    Ranibizumab (Lucentis), an inhibitor of multiple vascular endothelial growth factor A isoforms, is approved for the intravitreal treatment of neovascular (wet) age-related macular degeneration (AMD). In clinical trials in patients with neovascular AMD, monthly or less frequent injections of...

  • Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Grewal, D S; Gill, M K; Sarezky, D; Lyon, A T; Mirza, R G // Eye;Jul2014, Vol. 28 Issue 7, p895 

    PurposeTo describe the efficacy of intravitreal aflibercept on 12-month visual and anatomical outcomes in patients with neovascular age-related macular degeneration (AMD) recalcitrant to prior monthly intravitreal bevacizumab or ranibizumab.MethodsNon-comparative case series of 21 eyes of 21 AMD...

  • Silicone deposits in repackaged anti-VEGF may cause permanent IOP spikes. Kahook, Malik Y. // Ocular Surgery News;2/25/2011, Vol. 29 Issue 4, p15 

    The article focuses on the occurrence of intraocular pressure (IOP) spikes of patients that receive intravitreal injections, wherein it is said that IOP spikes is due to the silicone oil deposits that leach from the repackage vials of anti-vascular endothelial growth factor (VEGF) agents.

  • Characteristics of fine vascular network pattern associated with recurrence of polypoidal choroidal vasculopathy. Oishi, A.; Mandai, M.; Kimakura, M.; Nishida, A.; Kurimoto, Y. // Eye;Aug2011, Vol. 25 Issue 8, p1020 

    ObjectiveTo characterize an irregular capillary-like structure in the vascular network of eyes with polypoidal choroidal vasculopathy (PCV), and to determine whether its presence after photodynamic therapy (PDT) can be used to predict the clinical course of PCV.MethodsWe reviewed the clinical...

  • Age-related macular degeneration. Ong, B. B.; Ah-Fat, F. G. // British Journal of Hospital Medicine (17508460);Feb2016, Vol. 77 Issue 2, pC18 

    The article discusses clinical information on age-related macular degeneration (AMD). Topics explored include the percentage of visual impairment cases in Great Britain which may be attributed to AMD, pathophysiological factors which characterize geographic atrophy and exudative AMD, and...

  • Novel anti-VEGF agent may provide key advancement in AMD treatment. Guttman Krader, Cheryl // Ophthalmology Times;Jul2015, Vol. 40 Issue 12, p13 

    The article reports that a pivotal trial will soon be underway with positive results achieved in phase II of OSPREY trial investigating RTH258, a novel anti-vascular endothelial growth factor (VEGF) agent to treat wet age-related macular degeneration (AMD). Topics discussed include finding of...

  • VMA does not affect visual acuity after anti-VEGF injections for polypoidal choroidal vasculopathy. Kronemyer, Bob // Ocular Surgery News;2/25/2014, Vol. 32 Issue 4, p26 

    The article reports that posterior vitreomacular adhesion (VMA) was not associated with visual outcomes after intravitreal anti-vascular endothelial growth factor (VEGF) therapy for polypoidal choroidal vasculopath based on a study led by ophthalmologist Dr. Han Joo Cho. Topics discussed include...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics